Editors: Atta-ur-Rahman , M. Iqbal Choudhary

Frontiers in Anti-Cancer Drug Discovery

Volume 4

Personal Book: US $99 Special Offer (PDF + Printed Copy): US $177
Printed Copy: US $128
Library Book: US $396
ISSN: 2451-8395
eISSN: 1879-6656 (Online)
ISBN: 978-1-60805-923-2
eISBN: 978-1-60805-922-5 (Online)
Year of Publication: 2014
DOI: 10.2174/9781608592251140401

Introduction

Frontiers in Anti-Cancer Drug Discovery is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Cancer drug design and discovery. Each volume is devoted to the major advances in Anti-Cancer drug design and discovery. The Ebook series is essential reading for all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Indexed in: EMBASE, EBSCO, Ulrich's Periodicals Directory.

Contributors

Editor(s):
FRS Atta-ur-Rahman
University of Cambridge
Kings College
Cambridge
UK


M. Iqbal Choudhary
Biological Sciences
H.E.J. Research Institute of Chemistry
University of Karachi
Karachi, 75270
Pakistan




Contributor(s):
Alexandra Canonici
National Institute for Cellular Biotechnology
Dublin City University
Ireland


Brigid C. Browne
The Kinghorn Cancer Centre
Garvan Institute of Medical Research
Sydney
Australia


Denis M. Collins
National Institute for Cellular Biotechnology
Dublin City University
Ireland


Denise de Oliveira Silva
Department of Fundamental Chemistry
Institute of Chemistry, University of São
Paulo, Av. Prof. Lineu Prestes, 748,
São Paulo
SP, 05508-000
Brazil


Elliot B. Tapper
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Hiroki Takahashi
Department of Surgery
Kurume University
Kurume
Japan


Johanna Wassermann
Department of Medical Oncology,
La Pitié Salpêtrière University Hospital
Assistance Publique-Hôpitaux de Paris
Paris
France


John Crown
National Institute for Cellular Biotechnology
Dublin City University
St. Vincent’s University Hospital
Dublin
Ireland


Karen Howe
National Institute for Cellular Biotechnology
Dublin City University,
Ireland


Keisuke Miwa
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Kotaro Yuge
Multidisciplinary Cancer Treatment Center,
Kurume University
Kurume,
Japan


Lili Feng
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston
MA
USA
/
Department of Hematology
Provincial Hospital Affiliated to Shandong University
Jinan
P.R.
China


Mai Mishima
Department of Surgery
Kurume University
Kurume
Japan


Maki Tanaka
Kurume General Hospital
Kurume
Japan


Marina Gehring
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston
MA
USA


Martina S.J. McDermott
Department of Drug Discovery and Biomedical Sciences
South Carolina College of Pharmacy
University of South Carolina
Columbia


Masaru Fukahori
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Masayoshi Kage
Center for Innovative Cancer Therapy
Kurume University
Kurume
Japan
/
Department of Pathology
Kurume University
Kurume
Japan


Miguel Muñoz
Research Laboratory on Neuropeptides (IBIS)
Virgen del Rocío University Hospital
Sevilla
Spain


Miki Takenaka
Department of Surgery
Kurume University,
Kurume
Japan


Mohamed Bouattour
Department of Hepatology
Beaujon University Hospital
Assistance Publique-Hôpitaux de Paris,
Paris
France


Mototsugu Matsunaga
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Neil A. O’Brien
Department of Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles
CA
USA


Nobutaka Iwakuma
Department of Surgery
Kurume University
Kurume
Japan


Norma O’Donovan
National Institute for Cellular Biotechnology
Dublin City University
Ireland


Rafael Coveñas
Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14)
Institute of Neurosciences of Castilla y León (INCYL)
University of Salamanca
Salamanca
Spain


Ryuji Takahashi
Department of Surgery
Kurume University
Kurume
Japan


Shino Nakagawa
National Hospital Organization Kyushu Medical Cancer
Breast Care Center
Clinical Research Institute
Fukuoka
Japan


Simon C. Robson
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Teruhiko Fujii
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan
/
Center for Innovative Cancer Therapy,
Kurume University
Kurume
Japan


Tomoyuki Ushijima
Multidisciplinary Cancer Treatment Center
Kurume University
Kurume
Japan


Uhi Toh
Department of Surgery
Kurume University
Kurume
Japan


Xiaofeng Sun
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Yan Wu
Division of Gastroenterology, Department of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston
MA
USA


Yoshito Akagi
Department of Surgery
Kurume University
Kurume
Japan